A Moderate to Severe Rheumatoid Arthritis Study

NCT01721044 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

527

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Placebo
DRUG: Baricitinib
DRUG: cDMARD

Sponsor

Eli Lilly and Company